Navigation Links
Biomarkers and Innovation Push Global Cancer Diagnostics Market Toward $8 Billion
Date:3/12/2008

NEW YORK, March 12 /PRNewswire/ -- The world market for in vitro diagnostic (IVD) tests for cancer is growing at nearly 11% annually and could reach nearly $8 billion by the end of 2012, according to a new study released today by Kalorama Information. In addition to demographic and epidemiologic shifts, the cancer testing market is being driven by a number of advances in traditional technologies, biomarker development, and new clinical priorities.

According to the study, The Worldwide Market for Cancer Diagnostics, 3rd Edition, the increased level of cancer screening, a public health priority as well as a healthcare cost priority, continues to drive some basic testing techniques such as fecal occult blood testing. However, advances in pharmacodiagnostic technologies aimed at refining treatment options and genetic and molecular tests to determine tumor growth pathways in the evaluation of patients at risk are creating exciting opportunities for research development and offer the potential to open new market niches.

In addition to technology, the report notes that the emergence of the new paradigm that views cancer as a chronic disease has also been a boon for IVD developers. With advances in early screening and improved therapeutics, there is more need for cancer management and monitoring tests.

"One of the most exciting aspects of the current cancer diagnostics market is the high level of collaboration we're seeing among complementary technologies," notes Shara Rosen, the author of the report. "New products will be made up of a mix of component parts from different platform companies, information technology providers, and reagent companies."

Kalorama Information's report The Worldwide Market for Cancer Diagnostics, 3rd Edition includes market size and growth forecasts to 2012; market segmentations by cancer type, IVD discipline, and geography; extensive discussions of technology development and penetration; and profiles of over 150 companies active in the segment. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Worldwide-Cancer-Diagnostics-1393082/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Biomarkers for Mood May Alter Psychiatric Treatments
2. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
3. Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer
4. New developments in biomarkers for epithelial ovarian cancer
5. Biomarkers for Alzheimers disease can be trusted in clinical trials
6. JDRF and Lilly partner to fund research to identify beta cell biomarkers
7. Biomarkers predict risk for invasive breast cancer years before the tumor develops
8. Study makes progress in zoning in on biomarkers for better colon cancer treatment
9. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
10. Pharos Innovations Announces First Recipient of National Award for Achievements in Chronic Care Programs and Research
11. Surgery looks at inventions and innovations by surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... NEW YORK (PRWEB) , ... March 28, 2017 ... ... development, NTX Technology™, is the first technology to directly address the resolution to ... Organization. NTX Technology™ is a patented compound of FDA and TTB approved ingredients ...
(Date:3/28/2017)... ... ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of ... Dr. Wentz talked about journey and research recently on a blog and discussed some ... only solution to deal with thyroid disease. , Dr. Wentz completed her graduation ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a ... Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are ... of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... instruments are critical to ensuring high-quality results and maintaining GMP and USP compliance. ... Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... corrosive ions found in power plant water and steam. , Chlorides and sulfates ... and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/28/2017)... LONDON , March 28, 2017  "US ... insight on the various indicators and trend analysis ... generics drugs in mainstream pharmaceutical market in US. ... responsible for the growth on cancer generics drugs ... resulted in saving of billions of dollars for ...
(Date:3/28/2017)... 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2016. ... transformational progress for Orexigen, beginning with the re-acquisition of ... early March, the team at Orexigen demonstrated remarkable focus, ... reshaped and strengthened our Company while rewarding us full ...
Breaking Medicine Technology: